

Mini Review

Metoclopramide: An Antiemetic in Chemotherapy Induced Nausea and Vomiting

Signe Ladegaard Harder¹ and Jørn Herrstedt^{2*}¹Department of Oncology, Odense University Hospital, Denmark²Department of Oncology, Odense University Hospital and the University of Southern Denmark, Denmark

*Corresponding author

Jørn Herrstedt, Department of Oncology, Odense University Hospital, DK-5000, Odense C, Denmark, Tel: 45-6541-3634; Email: herrstedt@rsyd.dk

Submitted: 13 January 2017

Accepted: 16 March 2017

Published: 17 March 2017

ISSN: 2379-089X

Copyright

© 2017 Herrstedt et al.

OPEN ACCESS

Keywords

- Metoclopramide
- Chemotherapy
- Nausea
- Vomiting
- Emesis

Abstract

Chemotherapy induced nausea and vomiting (CINV) are two of the most feared adverse events experienced by cancer patients undergoing chemotherapy. Metoclopramide was derived from procainamide in the 1950s and one of the first drugs investigated in the prophylaxis of nausea and vomiting induced by chemotherapy. The breakthrough came in 1981 with the recognition that high-dose metoclopramide was effective and tolerable in the prevention of cisplatin-induced nausea and vomiting. A combination of high-dose metoclopramide and a corticosteroid was the standard antiemetic recommendation until the serotonin (5-HT)₃-receptor antagonists, ondansetron, granisetron, tropisetron and dolasetron became available in the beginning of the 1990s.

The development of these highly selective (5-HT)₃-receptor antagonists with a superior effect and a preferable tolerability profile has limited the use of metoclopramide to be prescribed as a rescue antiemetic, when guideline recommended antiemetic therapy fails.

ABBREVIATIONS

CINV: Chemotherapy-Induced Nausea and Vomiting; MCP: Metoclopramide; NK₁-Receptor Antagonist: Neurokinin (NK)₁-Receptor Antagonist; 5-HT₃-Receptor Antagonist: 5-Hydroxytryptamine (5-HT)₃-Receptor Antagonist

INTRODUCTION

Metoclopramide (MCP) is a dopamine receptor antagonist, and is the most intensively investigated drug of this class as regards prophylaxis of chemotherapy-induced nausea and vomiting (CINV).

MCP (2-methoxy-5-chloro-procainamide) was originated in the 1950s as a substituted benzamide derived from procainamide a drug with local anesthetic and antiarrhythmic properties [1]. In therapeutic doses, MCP is almost devoid of these effects, but instead enhances gastrointestinal motility and possesses antiemetic effect.

MCP was tested in the early 1960s by Justin-Besancon, Laville, and Thominet [2] and soon proved to be effective against nausea and vomiting induced by a number of non-malignant conditions such as dyspepsia, delayed gastric emptying and postoperative nausea and vomiting [1,3].

The emetic risk of chemotherapy is divided in high emetic risk (risk of vomiting 0-24 hours after chemotherapy > 90%), moderate emetic risk (30-90%), low emetic risk (10-30%) and minimal emetic risk (< 10%). This paper will review studies with MCP in the prophylaxis of nausea and vomiting in patients receiving high and moderate emetic risk chemotherapy, primarily cisplatin (high risk), anthracyclines (moderate risk), cyclophosphamide (moderate risk) and the combination of an anthracycline and cyclophosphamide (high risk). The most important randomized studies are summarized in Table 1.

The early trials (1960-1989)

Conventional, low doses of MCP: In randomized, double-blind trials, oral doses of MCP 20 mg x 2-3 were equal to placebo or to prochlorperazine, (but both were ineffective) and inferior to dexamethasone or domperidone against nausea and vomiting induced by both non-cisplatin-based and cisplatin-based chemotherapy [4-7]. It should be noticed, that in these early trials, only the first 24 hours after chemotherapy was evaluated, and it can therefore be concluded, that MCP in oral doses up to 20 mg is no better than placebo in the period 0-24 hours after chemotherapy. The interest in investigating MCP in conventional doses was therefore modest during the 1960s and 1970s.

Table 1: Important randomized studies 1960-2017 in the development of metoclopramide as an antiemetic in the prophylaxis of CINV.

Reference	Number of patients	Chemotherapy	Investigational Arm	Comparator	Primary parameter	Results*
Moertel et al. 1969 [4],	144	Non-CIS	MCP 20 mg x 3 po	PLA MPZ 5 mg x 3 po	Incidence of nausea and vomiting days 1-4	MCP = MPZ = PLA
Frytak et al. 1981 [6],	100	CIS	MCP 20 mg x 3 po	PCP	Vomiting	MCP > PCP, both ineffective
Gralla et al. 1981[8],	41	CIS	MCP 2 mg/kg x 5 iv	PLA PCP 10 mg x 5 im	Number of EE 0-24 hours	MCP > PLA MCP > PCP
Grunberg et al. 1984 [19],	28	CIS	MCP 2 mg/kg x 5 iv	HAL 3 mg/kg x 5 iv	Number of EE 0-24 hours	MCP > HAL
Kris et al. 1985 [9],	60(24 received 3 mg/kg x 2	CIS	MCP 2 mg/kg x 5 iv	MCP 3 mg/kg x 2 iv	Number of EE 0-24 hours	3 mg/kg x 2 iv = 2 mg/kg x 5 iv
Warrington et al. 1986 [11],	33	CIS	MCP 7 mg/kg divided in 5 bolus infusions + DEX 20 mg iv	MCP 3 mg/kg followed by 4 mg/kg (8 hour continuous infusion) + DEX 20 mg iv	Nausea and vomiting 0-24 hours	Nausea, vomiting and patient preference in favor of the continuous regimen
Kris et al. 1987 [22],	120	CIS	MCP 3mg/kg x 2 iv + DEX 20 mg iv + DPH 50 mg iv	MCP 3mg/kg x 2 iv + DEX 20 mg iv + L 1.5 mg/m2 iv	Number of EE 0-24 hours Safety	No difference in EE, but less restlessness with L
Roila et al. 1989 [10],	367	CIS	MCP 1 mg/kg x 4 iv + MP 250mg x 2 iv	MCP 3 mg/kg x 2 iv + DEX 20 mg iv + DPH 50 iv	Complete protection from vomiting/nausea 0-24 hours, Safety	MCP 3 mg/kg superior as concerns EE, nausea and safety (<extrapyramidal AE)
Marty et al. 1990 [33],	97	CIS	OND 8 mg iv + OND 1 mg/h iv for 24 hours	MCP 3 mg/kg iv + MCP 0.5 mg/kg/h for 8 hours	Number of patients with 0-2 EE 0-24h	OND > MCP
De Mulder et al. 1990 [34],	125	CIS	OND 8 mg iv + OND 1 mg/h iv for 24 hours + OND 8 mg x 3 po days 2-6	MCP 3 mg/kg iv + MCP 0.5 mg/kg/h for 8 hours+ MCP 20 mg x 3 po days 2-6	Number of patients with 0-2 EE 0-24 h Number of patients with 0-2 EE days 2-6	0-24 h: OND > MCP Day 2-6: Vomiting: OND = MCP Nausea:OND
Bonneterre et al. 1990 [39],	75	FAC or FEC	OND 4 mg iv + OND 4 mg po day 1 + OND 8 mg x 3 po for 3-5 days	MCP 60 mg iv + MCP 20 mg po day 1 + MCP 20 mg x 3 po for 3-5 days	Number with 0-2 EE (day 1) Number with 0-2 EE (days 2-3)	EE: OND > MCP (days 1-3) Nausea: OND > MCP (day 1) Nausea: OND = MCP (days 2-3)
Kaasa et al. 1990 [40],	93	AC or EC	OND 8 mg iv day 1 + OND 8 mg x 3 po for 3-5 days	MCP 60 mg iv + MCP 20 mg po x 3 for 3-5 days	EE (day 1) but not specified if the primary parameter was number with 0 EE or with 0-2 EE. EE (days 2-3) same comment	0 EE: OND > MCP (day 1) 0 EE: OND = MCP (days 2-3) Nausea: OND > MCP (day 1) Nausea: OND = MCP (days 2-3)
Marschner et al. 1991[41],	122	EC or FEC	OND 8 mg po + OND 8 mg x 3 po for 3-5 days	MCP 60 mg iv + MCP 20 mg po x 3 for 3-5 days	Number of patients with 0-2 EE 0-24 h.	OND = MCP
Warr et al. 1993 [35],	151	CIS	GRA 80 µg/kg iv	MCP 2 mg/kg x 5 iv+ DEX 10 mg iv + DPH10 mg iv	Mean nausea score (day 1) Number of patients with 0 EE (day 1)	GRA = DEX + MCP + DPH
Chevallier et al.1993 [36],	281	CIS	GRA 40 µg/kg iv +up to 2 more doses of GRA if breakthrough emesis within the first 24h	MCP 3 mg/kg iv + MCP 0.5 mg/kg/h for 8 hours + DEX 12 mg iv	Number of patients with no vomiting and no or only mild nausea 0-24 h	GRA = DEX + MCP
Roila et al. 2015 [52],	303 of 480 planned	CIS	PAL 0.25 mg iv + DEX 12 mg iv + APR 125 mg x 1 po day 1+ DEX 8 mg x 1 podays 2-4 + MCP 20 mg x 4 po days 2-4	PAL 0.25 mg iv + DEX 12 mg iv + APR 125 mg x 1 po day 1+DEX 8 mg x 1 po days 2-4+ APR80 mg x 1 podays 2-3	Complete response (no EE and no rescue antiemetics) days 2-5	MCP + DEX = APR + DEX

*> means a statistical significant difference; = means no statistical significant difference, but numerical differences may appear.
0-24 hours means from start of cisplatin infusion until 24 hours after. EE, emetic episodes; AE, adverse events; PCP, prochlorperazine; MCP, metoclopramide; DOM, domperidone; MPZ, metopimazine; DEX, dexamethasone; MP, methylprednisolone; DPH, diphenhydramine; L, lorazepam; HAL, haloperidol; OND, ondansetron; GRA, granisetron; PAL, palonosetron; PLA, placebo; APR, aprepitant; CIS, cisplatin; F, 5-fluorouracil; A, doxorubicin; E, epirubicin; C, cyclophosphamide.

High-dose MCP: Gralla and coworkers were some of the first to investigate the effect of high-dose MCP in prevention of cisplatin-induced nausea and vomiting [8]. Their study, published in 1981, actually consisted of two double-blinded randomized trials, the first comparing high-dose MCP to placebo ($n = 21$) and the second a comparison with prochlorperazine ($n = 20$). The dose of MCP was 2 mg/kg intravenously administered 5 times, starting 30 minutes before chemotherapy and ending 8.5 hours following cisplatin-based (120 mg/m^2) chemotherapy, yielding a total dose of MCP 10 mg/kg. The primary parameter was the number of emetic episodes within the first 24 hours following cisplatin. Patients receiving MCP had significantly fewer episodes of emesis than patients receiving placebo (median number of emetic episodes 1.0 versus 10.5, $p = 0.001$) or prochlorperazine (median 1.5 versus 12.0, $p = 0.005$). MCP also significantly reduced the volume of emesis and shortened the duration of nausea. Adverse events included mild sedation in 76 % of patients receiving MCP versus 50%/40% of patients receiving placebo/prochlorperazine, and one patient in the MCP group experienced an extrapyramidal reaction. This study is the most important one investigating the effect of MCP in CINV, because it was now possible for the first time to prevent nausea and vomiting in cisplatin-treated patients.

Subsequent studies tried to fine-tune the high-dose MCP regimen, by comparing 4-5 bolus doses of MCP 1-2 mg/kg with two bolus doses of 3 mg/kg [9,10] or with a bolus dose followed by continuous infusion of MCP [11]. Some of these studies also investigated if the antiemetic effect of MCP was correlated to the plasma concentration of MCP [11-16], but inconsistent results were obtained and no clear-cut plasma level was defined.

High-dose MCP was also investigated in non-cisplatin chemotherapy [17], but never obtained the same success as in cisplatin-based chemotherapy. Other dopamine receptor antagonists such as prochlorperazine [18] and haloperidol [19] were investigated in high doses and compared with high-dose MCP, but no advantages with any of these agents were observed.

High-dose MCP combined with a corticosteroid: Even though high-dose MCP was considered the golden standard of antiemetic treatment for patients receiving cisplatin-based chemotherapy, the treatment only prevented nausea and vomiting in about 30-40% of the patients [20]. In 1984-1987 a number of studies demonstrated that the addition of either methylprednisolone [21,22] or dexamethasone [23,24] improved the effect of MCP and in the same time reduced MCP induced adverse events, in particular diarrhea.

High-dose MCP combined with a corticosteroid and diphenhydramine or lorazepam: Acute dystonic reactions induced by high-dose MCP are a significant problem, particularly in younger patients [25,26]. It was soon verified that the addition of diphenhydramine or lorazepam resulted in a significant reduced incidence of extrapyramidal adverse effects. A modified high-dose MCP regimen ($3 \text{ mg/kg} \times 2 \text{ i.v.}$ or $4 \text{ mg/kg} \times 1 \text{ i.v.}$) combined with dexamethasone and lorazepam or diphenhydramine (to decrease the incidence of extrapyramidal adverse effects) was the standard regimen in cisplatin-based chemotherapy [10,27] until the serotonin receptor antagonists became available in the early 1990s.

The later trials (1990-1999)

High-dose MCP versus a serotonin-receptor antagonist: Studies published 1978-1986 demonstrated that the effect of high-dose MCP is not due to antagonism at dopamine receptors, but is caused by antagonism at 5-HT_3 receptors [28-31]. This recognition led to the development of a new class of antiemetic agents - the serotonin receptor antagonists of which the first clinical study was published in 1987 [32].

In 1990 two randomized double-blind studies in patients receiving cisplatin-based chemotherapy used a cross over design and compared the antiemetic effect of the serotonin receptor antagonist, ondansetron, with high dose MCP [33,34]. In the first [33] study ($n = 97$), ondansetron was more effective than MCP in the prevention of acute (0-24 hours) nausea and vomiting and more patients preferred the ondansetron regimen (55% versus 26%, $p = 0.006$). The second [34] study ($n = 125$) also found that ondansetron was superior to MCP in the first 24 hours after cisplatin and more patients preferred ondansetron (54% versus 30%, $p = 0.012$), but MCP was actually more effective in the prevention of delayed nausea (days 2-6, $p = 0.016$). Also other 5-HT_3 -receptor antagonists, such as granisetron [35, 36], tropisetron [37] and dolasetron [38] were compared to either MCP alone [38] or a combination of MCP and dexamethasone [35-37] in patients treated with cisplatin. The conclusion from these studies is that the 5-HT_3 -receptor antagonist was superior to single agent MCP [38] and non-inferior to the combination of MCP and dexamethasone [35-37].

Three randomized, double-blind studies published 1990-1991 compared MCP and ondansetron in patients receiving anthracycline-cyclophosphamide (AC)-based chemotherapy [39-41]. The AC combination was in 1990 classified as moderately emetogenic, but is today recognized as highly emetogenic [42]. In two studies including a total of 178 evaluable patients [39,41], all were women with breast cancer, and in the third study [39] the majority ($n = 51$) were women with breast cancer as well, but also patients with non-Hodgkin's lymphoma ($n = 31$) and other tumor types ($n = 11$) were included. In two trials, ondansetron was significantly superior to MCP as concerns acute (0-24 hours) vomiting and nausea [39,40] and ondansetron was in one of these studies [39] also significantly superior in the prevention of vomiting (but not nausea) days 2-3. In the third trial [41] no statistical significant differences were seen.

These studies led to a shift in standard antiemetic therapy for both cisplatin-based and AC-based chemotherapy. A 5-HT_3 -receptor antagonist was now recommended instead of MCP and subsequent studies demonstrated the advantage of combining a 5-HT_3 -receptor antagonist with dexamethasone [43] and this combination was the golden standard until the first NK_1 -receptor antagonist, aprepitant, became available in 2003.

MCP in the prevention of delayed nausea and vomiting: Until the mid-1980s, the vast majority of antiemetic studies evaluated patients during the first 24 hours after chemotherapy, only. Kris et al., extended the observation time to include the period from 24-120 hours after cisplatin-based chemotherapy and antiemetic prophylaxis with high-dose MCP ($3 \text{ mg/kg} \times 2 \text{ i.v.}$) plus dexamethasone 20 mg i.v. combined with either

diphenhydramine or lorazepam to avoid extrapyramidal adverse reactions from MCP [44]. Patients received a prescription for oral prochlorperazine to be taken in case of delayed symptoms, but no routine antiemetics were prescribed. Although 63% of the patients did not vomit in the first 24 hours, both vomiting and nausea were frequently reported 24-120 hours after cisplatin, and particular day 3 (48-72 hours) were troublesome with 78% and 61% suffering from delayed nausea and vomiting, respectively [44]. In a subsequent trial, the same group randomized patients treated with high-dose cisplatin to delayed antiemetic prophylaxis with placebo, dexamethasone alone or dexamethasone plus MCP and found that the combination was superior to placebo and to dexamethasone alone [45]. Subsequent studies have confirmed the effect of this combination in the prophylaxis of delayed nausea and vomiting [46,47].

The newest trials and the evidence-based guidelines (2000-2017)

The first clinical trial with an NK₁-receptor antagonist was published in 1997 [48]. Today three agents of this drug class have been marketed, namely aprepitant, rolapitant and netupitant (given as NEPA in combination with the 5-HT₃-receptor antagonist, palonosetron). The recent interest in investigating MCP has been modest, because the 5-HT₃-receptor antagonists are superior with a more preferable adverse event profile. Therefore evidence-based guidelines of today do not recommend MCP (or other dopamine receptor antagonists) for routine use. MCP is therefore primarily recommended as a rescue antiemetic, when routine antiemetic therapy fails [42,43].

There are a few exceptions from the above statement. MCP is recommended (equally with dexamethasone or a 5-HT₃-receptor antagonist) in the prophylaxis of acute nausea and vomiting induced by chemotherapy with a low emetogenic potential [49]. Also MCP is recommended in the treatment of nausea and vomiting not induced by chemotherapy in patients with advanced cancer [50] and as prophylaxis or rescue in patients receiving radiotherapy of a low or minimal emetogenic potential [51], but none of these indications are within the scope of this review.

A recent study re-addressed the potential use of MCP as part of an antiemetic combination in the prophylaxis of delayed nausea and vomiting following cisplatin-based (≥ 50 mg/m²) chemotherapy. In a randomized, double-blind study in which all patients (n = 303) received the same antiemetic prophylaxis for acute nausea and vomiting, patients were randomized to either dexamethasone plus aprepitant or to dexamethasone plus metoclopramide for delayed emesis protection [52]. Both combinations were equally effective in the prevention of delayed nausea and vomiting, and current guidelines therefore recommend the use of dexamethasone combined with either MCP or aprepitant in patients receiving non-AC highly emetogenic chemotherapy and aprepitant, a 5-HT₃-receptor antagonist and dexamethasone for acute CINV prophylaxis [42]. If another NK₁-receptor antagonist (rolapitant or netupitant) is used for prophylaxis day 1, dexamethasone alone is recommended [42].

Safety of metoclopramide: Common side-effects (≥ 1 % of patients) include somnolence, diarrhea, hypotension, akathisia, dry mouth, depression, fatigue and extrapyramidal symptoms

[25,26] which can all be dose limiting. As previously mentioned, the addition of diphenhydramine or lorazepam to high-dose metoclopramide decreases the risk of extrapyramidal symptoms [10,26,27]. Metoclopramide must be used with caution in younger female patients in whom the risk of neurological side-effects is particularly high [53].

Both The European Medicines Agency (EMA) and The Food and Drug Administration (FDA) have advised against long-term use and use of high doses [54,55]. This means that metoclopramide is not to be used for more than five days and in a maximum dose of 10 mg x 3 daily. This is of course a barrier to the use as an antiemetic in CINV.

CONCLUSION

Although not originally developed as an antiemetic (contrary to the selective 5-HT₃- and NK₁-receptor antagonist antiemetics), MCP became the first milestone in the prophylaxis of CINV. This was primarily due to the effect of high-dose MCP, which was the first effective regimen in the prevention of cisplatin induced emesis [8], a group of patients previously facing an almost 100% risk of vomiting.

In countries with access to 5-HT₃-receptor antagonists and NK₁-receptor antagonists, MCP is rarely used as a routine antiemetic prophylaxis, but is still important as a rescue antiemetic. The modest pricing of metoclopramide compared to the more modern antiemetics still makes MCP an important resource in low-income countries.

REFERENCES

- Schulze-Delrieu K. Metoclopramide. *Gastroenterol.* 1979; 77: 768-779.
- Justin-Besancon L, Laville C, Thominet M. Le métoclopramide et ses homologues. Introduction à leur étude biologique. *CR AcadSci (Paris).* 1964; 258: 4384-4386.
- Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Metoclopramide: a review of its pharmacological properties and clinical use. *Drugs.* 1976; 12: 81-131.
- Moertel C, Reitemeier RJ. Controlled clinical studies of orally administered antiemetic drugs. *Gastroenterology.* 1969; 57: 262-268.
- Arnold DJ, Ribiero V, Bulkin W. Metoclopramide versus prochlorperazine in the prevention of vomiting from cisdiamminedichloroplatinum. *Proc Am Soc Clin Oncol.* 1980; 21: 344.
- Frytak S, Moertel CG, Eagan RT, O'Fallon JR. A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy. *Proc Am Soc Clin Oncol.* 1981; 22: 421.
- Cunningham D, Evans C, Gazet JC, Ford H, Pople A, Dearling J, et al. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. *BMJ.* 1987; 295: 250.
- Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW Jr, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. *N Engl J Med.* 1981; 305: 905-909.
- Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide,

- dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. *Cancer*. 1985; 55: 527-534.
10. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. *J Clin Oncol*. 1989; 7: 1693-1700.
11. Warrington PS, Allan SG, Cornbleet MA, MacPherson JS, Smyth JF, Leonard RCF. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. *BMJ*. 1986; 293: 1334-1337.
12. Meyer BR, Lewin M, Drayer DE, Pasmantier M, Lonski L, Reidenberg MM. Optimizing metoclopramide control of cisplatin-induced emesis. *Ann Intern Med*. 1984; 100: 393-395.
13. Mc Dermid JE, Cohen JL, Joseph C, Strum SB. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. *J Clin Oncol*. 1985; 3: 1400-1408.
14. Taylor WB, Proctor SJ, Bateman DN. Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic induced vomiting. *Br J Clin Pharmacol*. 1984; 18: 679-684.
15. Grunberg SM, Mc Dermid JE, Bernstein JE, Cohen J. Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin. *Cancer Chemother Pharmacol*. 1987; 20: 332-336.
16. Herrstedt J, Hannibal J, Hallas J, Andersen E, Laursen LC, Hansen M. High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam plus dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. *Ann Oncol*. 1991; 2: 223-227.
17. Cunningham D, Soukop M, Gilchrist NL, Forrest GJ, Hepplestone A, Calder IT, et al. Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. *Br Med J (Clin Res Ed)*. 1985; 290: 604-605.
18. Olver IN, Wolf M, Laidlaw C, Bishop JF, Cooper IA, Matthews J, et al. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. *Eur J Cancer*. 1992; 28A: 1798-1802.
19. Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind trial. *J Clin Oncol*. 1984; 2: 782-787.
20. Allan SG, Cornbleet MA, Lockhart SP, Warrington PS, Leonard RCF, Smyth J. Emesis due to cancer chemotherapy: results of a prospective, randomized, double-blind trial of varying doses of metoclopramide in the management of cis-platinum-induced vomiting. *Eur J Cancer Clin Oncol*. 1984; 20: 1481-1484.
21. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. *J Clin Oncol*. 1987; 5: 141-149.
22. Díaz-Rubio E, González-Larriba JL, Rosell R, Abad A, Martín M, Valerdi JJ, et al. Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone. *Ann Oncol*. 1990; 1: 379-380.
23. Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RC, Smyth JN. Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. *BMJ*. 1984; 289: 878-879.
24. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatin-induced emesis. *Cancer Invest*. 1986; 4: 379-385.
25. Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK. Extrapyramidal reactions with high-dose metoclopramide. *N Engl J Med*. 1983; 309: 433.
26. Grunberg SM, Ehler E, Mc Dermid JE, Akerley WL. Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. *J Natl Cancer Inst*. 1988; 80: 864-868.
27. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of antiemetic cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide and dexamethasone. *Cancer*. 1987; 60: 2816-2822.
28. Fozard JR, Mobarok Ali AT. Blockade of neuronal tryptamine receptors by metoclopramide. *Eur J Pharmacol*. 1978; 49: 109-112.
29. Fozard JR. MDL 72222, a potent and highly antagonist at neuronal 5-hydroxytryptamine receptors. *Naunyn Schmiedeberg Arch Pharmacol*. 1984; 326: 36-44.
30. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M receptor antagonism. *Br J Pharmacol*. 1986; 88: 497-499.
31. Costall B, Domeney AM, Naylor RJ, Tattersall FD. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. *Neuropharmacology*. 1986; 25: 959-961.
32. Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT₃ receptor antagonist) in prevention of chemotherapy-induced emesis. *The Lancet*. 1987; 329: 1198.
33. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, et al. Comparison of the 5-hydroxytryptamine₃ (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. *N Engl J Med*. 1990; 322: 816-821.
34. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. *Ann Intern Med*. 1990; 113: 834-840.
35. Warr D, Wilan A, Venner P, Pater J, Kaizer L, Laberge F, et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. *An NCI Canada Clinical Trials Group Phase III Trial*. *Eur J Cancer*. 1993; 29A: 33-36.
36. Chevallier B. The control of acute cisplatin-induced emesis-a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. *Granisetron Study Group*. *Br J Cancer*. 1993; 68: 176-180.
37. Sorbe BG, Högberg T, Glimelius B, Schmidt MS, Wernstedt L, Hansen O, et al. A randomised, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT₃ receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. *Cancer*. 1994; 73: 445-454.
38. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, et al. A double-blind, multicentre comparison of intravenous dolasetronmesilate and metoclopramide in the prevention of

- nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. *Support Care Cancer*. 1997; 5: 22-30.
39. Bonnetterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. *J Clin Oncol*. 1990; 8: 1063-1069.
40. Kaasa S, Kvaløy S, Dicato MA, Ries F, Huys JV, Royer E, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. *International Emesis Study Group. Eur J Cancer*. 1990; 26: 311-314.
41. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. *Eur J Cancer*. 1991; 27: 1137-1140.
42. Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et al. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high emetic risk chemotherapy. *Support Care Cancer* 2017; 25: 277-288.
43. Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. *Ann Oncol*. 2006; 17: 20-28.
44. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. *J Clin Oncol*. 1985; 3: 1379-1384.
45. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. *J Clin Oncol*. 1989; 7: 108-114.
46. Moreno I, Rosell R, Abad A, Barnadas A, Carles J, Ribelles N, et al. Comparison of three protracted regimens for the control of delayed emesis in cisplatin-treated patients. *Eur J Cancer*. 1992; 28A: 1344-1347.
47. Italian Group for Antiemetic Research (IGAR). Ondansetron versus metoclopramide both combined with dexamethasone, in the prevention of delayed cisplatin-induced emesis. *J Clin Oncol* 1997; 15: 124-130.
48. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK₁ receptor antagonist to prevent delayed emesis after cisplatin. *J Natl Cancer Inst*. 1997; 89: 817-818.
49. Olver I, Ruhlmann CH, Jahn F, Schwartzberg L, Rapoport B, Rittenberg CN, et al. 2016 updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. *Support Care Cancer*. 2017; 25: 297-301.
50. Walsh D, Davis M, Ripamonti, Bruera E, Davies A, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer. *J Support Care Cancer* 2017; 25: 333-340.
51. Ruhlmann CH, Jahn F, Jordan K, Dennis K, Maranzo E, Molassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: Prevention of radio-therapy-induced nausea and vomiting. *Support Care Cancer*. 2017; 25: 309-316.
52. Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. *Ann Oncol*. 2015; 26: 1248-1253.
53. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. *Br Med J (Clin Res Ed)*. 1985; 291: 930-932.
54. European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. 2013. (accessed March 06, 2017).
55. Food and Drug Administration. Press Announcements - FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. 2009. (accessed March 06, 2017).

Cite this article

Harder SL, Herrstedt J (2017) Metoclopramide: An Antiemetic in Chemotherapy Induced Nausea and Vomiting. *J Drug Des Res* 4(2): 1037.